The assay was carried out according to the method mentioned in a previous study [23] . We collected breast cancer tissues from patients from the First A liated Hospital of China Medical University. The
ISH probes were ordered from BOSTER Biological Technology Co., Ltd. (USA). For the IHC assays, we collected breast cancer tissues from different groups of subcutaneous. The details of all antibodies used are shown in Table S1.
Biotin pull-down MCF-7 cell lysates were incubated with
CBR3-AS1 or control probe (Sangon, China) conjugated to streptavidin agarose resin beads (Thermo Fisher Scienti c, USA) to generate probe-bound Dynabeads.
After the samples were washed with buffer, DNase I (20 U) was added, and puri ed RNA was collected. The puri ed RNA was analysed by qRT-PCR. The whole experimental process and the buffer formulation were described by Hsu et al [24] .
Zhang M., Wang Y., Jiang L., Song X., Zheng A., Gao H., Wei M., & Zhao L. (2021). LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4‑mediated MAPK signal pathway.